Allison Luo

Statistics

Publications

Citations

1.4K

H-Index

Active since

2007

Affiliations

Bristol-Myers Squibb (United States)(Current)

Icahn School of Medicine at Mount Sinai

University of California San Diego

Western University

KU Leuven

Allison Luo is an author at Bristol-Myers Squibb (United States) specializing in inflammatory bowel disease therapy, inflammation, and inflammatory bowel disease.

ORCID

Publications per year

2007–2025

Publications

Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.

Jeffrey Kaine, Alan Kivitz, C. Birbara et al. · PubMed · 2007 · 244 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Michael Yellin, I.A. Paliienko, Andra Bălănescu et al. · Arthritis & Rheumatism · 2011 · 197 citations

Medicine, Pharmacology, Pharmacotherapy +15

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

Lloyd Mayer, William J. Sandborn, Yu.M. Stepanov et al. · Gut · 2013 · 192 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Abatacept for Crohn's Disease and Ulcerative Colitis

William J. Sandborn, Jean‐Frédéric Colombel, Bruce E. Sands et al. · Gastroenterology · 2012 · 139 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +11

Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program

Michael E. Weinblatt, Larry W. Moreland, René Westhovens et al. · The Journal of Rheumatology · 2013 · 136 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +16

1–5 of 17